Literature DB >> 18184917

Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.

J J Kragt1, A J Thompson, X Montalban, M Tintoré, J Río, C H Polman, B M J Uitdehaag.   

Abstract

INTRODUCTION: We studied the responsiveness and predictive value of two widely used clinical outcome measures that document multiple sclerosis (MS) disease progression-the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC)-in patients with primary progressive (PP) MS. Disease course in PPMS shows less fluctuation than in relapsing remitting (RR) MS.
METHODS: In a group of 161 patients with PPMS, EDSS and MSFC were performed at three timepoints. To assess responsiveness, mean change scores and variances were plotted against baseline scores and effect sizes were calculated. Predictive value was determined by calculating sensitivity, specificity, and likelihood ratios (LRs) of 1-year changes to predict changes over 2 years. Furthermore, multivariate logistic regression models were used to assess the predictive value of short-term worsening on EDSS and MSFC.
RESULTS: Responsiveness of both EDSS and MSFC was shown to be limited and mean changes were highly dependent on the baseline scores. Effect sizes for EDSS and MSFC were small and inconclusive (0.239 and 0.161). The predictive value of a short-term worsening (baseline to year 1) to predict worsening in the long term (baseline to year 2) was expressed for EDSS by a sensitivity of 0.55 and a LR+ of 8.64. For MSFC, sensitivity was 0.68 and LR+ was 3.14. However, short-term worsening was a poor predictor of subsequent worsening (year 1 to year 2) for EDSS (LR+ 1.06) and this relationship was actually inverse for MSFC (LR+ 0.61).
CONCLUSION: In this study over a period of 2 years in primary progressive multiple sclerosis, the Multiple Sclerosis Functional Composite (MSFC) was less responsive than the Expanded Disability Status Scale (EDSS). The predictive value of neither EDSS nor MSFC was very powerful.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184917     DOI: 10.1212/01.wnl.0000288179.86056.e1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Authors:  Myla D Goldman; Robert W Motl; Richard A Rudick
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 2.  Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Authors:  Carmen Tur; Marcello Moccia; Frederik Barkhof; Jeremy Chataway; Jaume Sastre-Garriga; Alan J Thompson; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2018-01-12       Impact factor: 42.937

3.  Quantitative measures detect sensory and motor impairments in multiple sclerosis.

Authors:  Scott D Newsome; Joseph I Wang; Jonathan Y Kang; Peter A Calabresi; Kathleen M Zackowski
Journal:  J Neurol Sci       Date:  2011-04-01       Impact factor: 3.181

Review 4.  Progressive multiple sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Curr Opin Neurol       Date:  2015-06       Impact factor: 5.710

Review 5.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Authors:  Daniel Ontaneda; Robert J Fox; Jeremy Chataway
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

6.  A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis.

Authors:  Antonia Ceccarelli; Maria A Rocca; Paola Valsasina; Mariaemma Rodegher; Elisabetta Pagani; Andrea Falini; Giancarlo Comi; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

7.  Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS.

Authors:  Elizabeth A Mills; Joel A Begay; Caitlyn Fisher; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2018-10-10       Impact factor: 6.312

8.  Changes in Multidigit Synergies and Their Feed-Forward Adjustments in Multiple Sclerosis.

Authors:  Hang Jin Jo; Daniela Mattos; Elisabeth B Lucassen; Xuemei Huang; Mark L Latash
Journal:  J Mot Behav       Date:  2016-08-11       Impact factor: 1.328

9.  Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS).

Authors:  James Twiss; Lynda C Doward; Stephen P McKenna; Benjamin Eckert
Journal:  Health Qual Life Outcomes       Date:  2010-10-11       Impact factor: 3.186

10.  Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials.

Authors:  Rotem Orbach; Zhenming Zhao; Yong-Cheng Wang; Gilmore O'Neill; Diego Cadavid
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.